RxDoctor Payments DataLook up a doctor →

Mohd Malik, MD

Psychiatry · Saint Louis, MONPI 1942208715

Payments from drug & device makers

$2,772,798in general payments, 2019–2025

Across 2,686 payments — averaging $1032.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$743K
  • Teva Pharmaceuticals USA, Inc.$387K
  • Alkermes, Inc.$348K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$233K
  • Hoffmann-la Roche Limited$216K
  • Otsuka America Pharmaceutical, Inc.$150K
  • plus $696K from 37 others
$375,687in research payments, 2019–2025

Across 69 payments — averaging $5444.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orexo US, Inc.$174K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$114K
  • Biohaven Pharmaceutical Holding Company Ltd.$64K
  • Teva Pharmaceuticals USA, Inc.$20K
  • E.r. Squibb & Sons, L.L.C.$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.314$743,194
Teva Pharmaceuticals USA, Inc.232$386,607
Alkermes, Inc.349$347,785
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)331$232,990
Hoffmann-la Roche Limited25$215,830
Otsuka America Pharmaceutical, Inc.257$150,160
Sunovion Pharmaceuticals Inc.306$141,662
Johnson & Johnson244$102,434
AbbVie(2 entities)211$99,065
H. Lundbeck A S5$54,317
Boehringer Ingelheim7$48,339
Axsome Therapeutics, Inc.43$38,321
Biogen3$36,484
Sage Therapeutics, LLC7$33,169
Otsuka Pharmaceutical Development & Commercialization, Inc.10$31,086
Sumitomo Pharma America, Inc.43$26,997
Indivior Inc.25$21,958
Neurocrine Biosciences, Inc.67$20,906
Genentech, Inc.3$20,768
Biohaven Pharmaceuticals, Inc.2$12,680
Orexo US, Inc.31$3,123
Validus Pharmaceuticals LLC17$1,164
Acadia Pharmaceuticals Inc7$669
Lundbeck LLC41$592
Takeda Pharmaceuticals U.S.A., Inc.17$467
Neuronetics, Inc.8$432
Vanda Pharmaceuticals Inc.27$365
Supernus Pharmaceuticals, Inc.16$263
E.r. Squibb & Sons, L.L.C.5$186
Noven Therapeutics, LLC12$182
Janssen Scientific Affairs, LLC2$154
Pfizer1$134
Eisai Inc.4$59
Almatica Pharma LLC2$53
Noven Pharmaceuticals, Inc.2$45
Neos Therapeutics, LP2$39
MDD US Operations, LLC2$25
Bausch Health US, LLC1$21
Ironshore Pharmaceuticals Inc.1$20
Shire North American Group Inc1$16
Sanofi1$12
Arbor Pharmaceuticals, Inc.1$12
Biohaven Pharmaceutical Holding Company Ltd.1$9

How this compares

$2,772,798 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri →

Medicare billing

Part B allowed, 2024
$40,643
Medicare patients
157
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Saint Louis

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →